• Medistim partners with LivaNova as their new distributor for India

  5. Jan 2021

  With its population size of about 1,4 billion, India is a large and emerging market for Medistim’s ultrasound devices.  Today, about 100,000 coronary bypass (CABG) procedures are performed in India annually, representing a market size…

  Read more

• Results for the Third Quarter 2020

  22. Oct 2020

  Sales for the quarter ended at MNOK 83.4 (MNOK 85.5), a decrease of 2,5%. Read the full report and presentation below. Q3 report 2020 Q3 presentation 2020

  Read more

• Webinar: Third Quarter Financial Results

  8. Oct 2020

  Sign up for the upcoming financial report presentation. You're invited to join this presentation on Thursday 22 October at 8 AM CEST. CEO Kari E. Krogstad and CFO Thomas Jakobsen will present the third quarter results,…

  Read more

• Results for the Second Quarter and First Half 2020

  17. Aug 2020

  Sales for the quarter ended at MNOK 82.5 (MNOK 93.8), a decrease of 12.2%. Sales for the 1st half ended at MNOK 185.6 (MNOK 182.5), a 1.7 % increase. Read the full report and presentation…

  Read more

• Webinar: Second Quarter and Half-yearly Financial Report

  30. Jun 2020

  Sign up for the upcoming financial report presentation. You're invited to join this presentation on Friday 14 August at 8 AM CEST. CEO Kari E. Krogstad and CFO Thomas Jakobsen will present the second quarter and…

  Read more

• Results for the First Quarter 2020

  29. Apr 2020

  Sales for the quarter ended at a record high MNOK 103.1 (MNOK 88.7), a 16.2% increase.This was driven by strong growth in capital sales of systems in Japan after regulatory approval of MiraQ™. Read the…

  Read more

• Annual Report 2019

  27. Mar 2020

  We have now achieved a market penetration of 23% in USA, measured as the share of bypass procedures done with Medistim’s devices. Our position in Asia and Europe is also strengthened, through increased sales and…

  Read more

• The REQUEST study is now published

  24. Mar 2020

  The REQUEST study is a multicenter, prospective study among 7 international centers performing coronary artery bypass grafting procedures.  The primary endpoint was any change in the planned surgical procedure. Major secondary endpoints consisted of the…

  Read more

• Results for Fourth Quarter and Preliminary Results for Medistim for 2019

  28. Feb 2020

  Sales for the quarter ended at MNOK 95.7 (MNOK 97.9), while sales for 2019 ended at MNOK 363.7 (MNOK 325.9), a growth of 11.6%. Q4 2019 PresentationQ4 and preliminary year-end financials 2019

  Read more

• Investor Presentation, March 3

  25. Feb 2020

  Medistim’s CEO Kari E. Krogstad will hold an investor presentation at the Carnegie Healthcare Seminar 2020 in Stockholm, Sweden. Date: Tuesday March 3, 2020 Venue: Regeringsgatan 56. 103 38 Stockholm For more information about this…

  Read more